Literature DB >> 12084254

Sexual function in patients with benign prostatic hyperplasia.

P K Hegarty1, N J Hegarty, J M Fitzpatrick.   

Abstract

Sexual health has significant impact on quality of life among men with benign prostatic hyperplasia (BPH). The degree of sexual dysfunction matches the severity of lower urinary tract symptoms (LUTS). Treatment of BPH affects not only LUTS, but sexual function as well. Medical, surgical, and minimally invasive therapies differ in their effect on erectile function, ejaculation, and sexual satisfaction. Choice of treatment modality takes into account baseline sexual function and patient expectations. This review outlines the relationship between LUTS and sexual function and how they change with the currently available treatments.

Entities:  

Mesh：

Year:  2001        PMID： 12084254     DOI： 10.1007/s11934-001-0066-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  54 in total

1.  Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study.

Authors:  Y Arai; Y Aoki; K Okubo; H Maeda; N Terada; Y Matsuta; S Maekawa; K Ogura
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

2.  Transurethral incision of prostate compared with transurethral resection of prostate in 132 matching cases.

Authors:  A Orandi
Journal:  J Urol       Date:  1987-10       Impact factor: 7.450

3.  Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience.

Authors:  S C Chueh; H J Yu; T Y Chiu; C Y Huang; M K Lai
Journal:  J Formos Med Assoc       Date:  1996-08       Impact factor: 3.282

4.  Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.

Authors:  J C Carraro; J P Raynaud; G Koch; G D Chisholm; F Di Silverio; P Teillac; F C Da Silva; J Cauquil; D K Chopin; F C Hamdy; M Hanus; D Hauri; A Kalinteris; J Marencak; A Perier; P Perrin
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

5.  Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.

Authors:  N P Roos; J E Wennberg; D J Malenka; E S Fisher; K McPherson; T F Andersen; M M Cohen; E Ramsey
Journal:  N Engl J Med       Date:  1989-04-27       Impact factor: 91.245

6.  Transurethral vaporization of the prostate: a promising new technique.

Authors:  K J Thomas; A J Cornaby; M Hammadeh; T Philp; P N Matthews
Journal:  Br J Urol       Date:  1997-02

Review 7.  Aging of the male reproductive system.

Authors:  M Hermann; G Untergasser; H Rumpold; P Berger
Journal:  Exp Gerontol       Date:  2000-12       Impact factor: 4.032

8.  Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  R Bruskewitz; C J Girman; J Fowler; O F Rigby; M Sullivan; R B Bracken; H A Fusilier; D Kozlowski; S D Kantor; E L Johnson; D Z Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

9.  The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

Authors:  G J Gormley; E Stoner; R C Bruskewitz; J Imperato-McGinley; P C Walsh; J D McConnell; G L Andriole; J Geller; B R Bracken; J S Tenover
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

10.  Double-blind randomized study of symptoms associated with absorption of glycine 1.5% or mannitol 3% during transurethral resection of the prostate.

Authors:  R G Hahn; L Sandfeldt; C R Nyman
Journal:  J Urol       Date:  1998-08       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.